排序方式: 共有18条查询结果,搜索用时 15 毫秒
1.
Amenorrhea is a common gynecological com-plaint more frequently seen in young women.Re-ports from various sources have appeared of latein which treatment of the disease involved theuse of tonics to restore the patient's health.Theviscera on which emphasis is laid are,however,varied.Most studies were conducted with theKidney as the organ to be reinforced.Next comes 相似文献
2.
3.
用化瘀通腑的内异1号丸治疗盆腔子宫内膜异位症76例,总有效率为80.26%。治疗前后分别作实验室检验,结果血液流变学包括全血比粘度(低切比)、红细胞聚集指数、全血还原粘度、血沉、血沉方程 K 值、血浆比粘度均有显著改变(P<0.05),血清IgA,IgG、IgM、C_3均有显著下降(P<0.001),OKT_8升高,OKT_4/OKT_8下降(P<0.001),经期血浆 PGF_(2a)下降(P<0.001)。提示化瘀通腑法和它的代表方内异1号丸具有改变血液流变性、改善微循环、调整机体免疫功能和降低经期血浆前列腺素浓度的作用,从而使患者的临床症状和体征得到改善。 相似文献
4.
5.
我科从1986~1987年,采用口服活血化瘀中药及丹参静脉滴注为主的多途径给药治疗12例子宫内膜异位症住院患者。取得一定疗效。小结如下。临床资料12例患者年龄在26~40岁之间,平均33.6岁。已婚11例.有不育史者4例,占已婚妇女的36.36%,其中2例各有一次流产病史。病程最短2个月,最长16年。12例中有4例在发病前2年内接受过人工流产术。皆有剧烈的经期和/或平时腹痛症状,有肛门坠 相似文献
6.
“内异灵片”治疗子宫内膜异位症的临床研究 总被引:1,自引:0,他引:1
用化瘀通腑、软坚散结法制成内异灵片治疗子宫内膜异位症患34例,同时设立西药(Tamoxifen)对照组18例。观察结果表明,内异灵片能显提高内异症患NK细胞的活性,调整T细胞的功能,维持人体免疫功能的稳定、改善患的各组症状和体征,临床有效率与Tamoxifen相仿。 相似文献
7.
8.
检测正常妇女及子宫内膜异位症患者经期血浆β-内啡肽、强啡肽水平及其动物模型下丘脑、垂体β-内啡肽、强啡肽水平。结果表明:子宫内膜异位症患者β-内啡肽、强啡肽水平低于正常妇女,可能是痛经的原因之一,内异Ⅱ号缓解痛经的作用,有部分可能是通过提高外周血及下丘脑β-内啡肽水平;子宫内膜异位症动物模型下丘脑、垂体β-内啡肽、强啡肽水平与正常对照组相比有明显的不同。 相似文献
9.
10.
Objective: To observe the clinical effect of Neiyifang (内异方,NYF) in treating endometri-osis and to explore its therapeutic mechanism through observing its influence on plasma β-endorphin β-EP) in different menstrual stages and levels of prostaglandins (PGs) in menstruation. Methods: NYF was administered to 104 patients with endometriosis one dose daily with 3 successive menstrual cycles as one therapeutic course. Peripheral blood β-EP level in follicular, luteal and menstrual stages, as well as PGF2a, PGE2, thromboxane B2 and 6-keto-PGF1a levels in menstrual stage were detected by RIA, and controlled with those in 15 healthy persons. Results: (1) The total effective rate of NYF was 81. 3% and it showed significant effect in improving patients' clinical symptoms and physical signs; (2) In menstrual stage, the levels of β-EP, 6-keto-PGF1α/ TXB2 were lower(P<0.05) and levels of PGF2a, PGE2, TXB2 and 6-keto-PGF1α, were higher (P<0. 05) in patients than those in control, and the higher the level of 相似文献